[EARS] Auris Medical Holding AG

Overview

Type of security: Stock

Sector: Health Care

Industry: Major Pharmaceuticals

Market Capitalization:

Exchange: NASDAQ

The data is delayed by 15 minutes.

 

Price: 1.18 Change: -0.04 (-3.28%)
Ext. hours: Change: 0 (0%)

chart EARS

Refresh chart

Strongest Trends Summary For EARS

EARS is in the medium-term down -20% below S&P in 7 months. In the long-term down -92% below S&P in 2 years and down -100% below S&P in 6 years.

Horizon: 3 hours | 2 days | 5 days | 10 days | 1 month | 6 months | 1 year | 2 years | 5 years | max

Chart type: absolute | relative to S&P

Publish chart

 

Description: Auris Medical Holding AG, a clinical-stage biopharmaceutical company, focuses on the development of novel products for the treatment of inner ear disorders. Its lead product candidate includes AM-101, which is in Phase III clinical trials for treating acute inner ear tinnitus. The company is also developing AM-111 for the treatment of acute sensorineural hearing loss, as well as for Meniere diseases; and other development programs comprising AM-102 and AM-123 that are in preclinical studies. It has a collaboration and license agreement with Xigen S.A. to develop, manufacture, and commercialize pharmaceutical products, and drug delivery devices and formulations for the treatment of inner ear disorders. The company was formerly known as Auris Medical AG and changed its name to Auris Medical Holding AG in April 2014. Auris Medical Holding AG was founded in 1998 and is headquartered in Zug, Switzerland.

See how to gain 20% in 14 sec with TrendsInvesting

Fundamental Ratios
Shares Outstanding EPS EPS Growth - 4 Quarters EPS Growth - Q/Q
EPS Growth - Y/Y Sales Growth - 4 Quarters Sales Growth - Q/Q P/E
P/E To EPS Growth P/S P/BV Price/Cash Per Share
Price/Free Cash Flow ROA-28.09% ROE-34.72% ROI
Current Ratio5.77 Quick Ratio Long Term Debt/Equity Debt Ratio0.2
Gross Margin Operating Margin Net Profit Margin Dividend Payout Ratio
Dividend Yield
Fundamental Data
Cash From Financing Activities10 K Cash From Investing Activities10 K Cash From Operating Activities-6.34 M Gross Profit
Net Profit-8.05 M Operating Profit-7.16 M Total Assets52.04 M Total Current Assets50.35 M
Total Current Liabilities5 M Total Debt Total Liabilities6.96 M Total Revenue
Technical Data
High 52 week14.38 Low 52 week1.35 Last close1.43 Last change1.42%
RSI25.37 Average true range0.12 Beta0.78 Volume51.3 K
Simple moving average 20 days-9.64% Simple moving average 50 days-33.5% Simple moving average 200 days-63.77%
Performance Data
Performance Week0.7% Performance Month-17.82% Performance Quart-47.43% Performance Half-47.04%
Performance Year-85.82% Performance Year-to-date-84.32% Volatility daily3.57% Volatility weekly7.97%
Volatility monthly16.34% Volatility yearly56.61% Relative Volume108.2% Average Volume138.04 K
New High New Low

News

2020-05-26 08:30:00 | Auris Medical Announces Positive Top-Line Data from AM-201 Phase 1b Study in Antipsychotic-Induced Weight Gain and Provides Update on TRAVERS Phase 2 Study

2020-05-10 10:39:38 | Here's Why We Worry About Auris Medical Holding's NASDAQ:EARS Cash Burn Situation

2020-04-16 07:00:00 | Auris Medical Provides Business Update and Reports Second Half and Full Year 2019 Financial Results

2020-04-03 17:00:00 | Auris Medical Provides Update on Intranasal Betahistine Development Program

2020-03-26 06:00:00 | Auris Medical Holding Ltd. to Host Earnings Call

2020-03-19 06:00:00 | Auris Medical Holding Ltd. to Host Earnings Call

2020-03-05 08:30:00 | Auris Medical Provides Update on Ongoing Clinical Trials with Intranasal Betahistine

2020-02-25 08:30:00 | Auris Medical Highlights Publication of Study Results Demonstrating Betahistine’s Antiepileptogenic and Anticonvulsant Activity in Murine Model

2020-02-10 10:01:12 | Should You Take Comfort From Insider Transactions At Auris Medical Holding Ltd. NASDAQ:EARS?

2020-01-10 08:30:00 | Auris Medical Announces Notice of Allowance for European Patent Application

2019-12-30 08:30:00 | Auris Medical Announces Formation of New Subsidiary for Development Projects in Tinnitus and Hearing Loss

2019-11-11 10:05:56 | Do Institutions Own Auris Medical Holding Ltd. NASDAQ:EARS Shares?

2019-10-11 08:30:00 | Auris Medical Announces Positive Interim Results from AM-201 Phase 1b Study in Antipsychotic-Induced Weight Gain

2019-09-13 09:00:00 | Auris Medical Receives FDA and EMA Guidance for Keyzilen® Late-Stage Clinical Development Program

2019-09-11 09:00:00 | Auris Medical Announces Notices of Allowance for U.S. and European Patent Applications Covering Intranasal Betahistine

2019-09-04 07:00:00 | Auris Medical Announces Appointment of New Chief Financial Officer

2019-08-26 09:00:00 | Auris Medical Announces Formation of Scientific Advisory Board for Tinnitus Programs

2019-08-23 10:21:02 | New Strong Sell Stocks for August 23rd

2019-08-22 10:06:02 | New Strong Sell Stocks for August 22nd

2019-08-15 07:00:00 | Auris Medical Provides Business Update and Reports First Half 2019 Financial Results

2019-07-30 08:30:00 | Auris Medical Announces Randomization of First Patient in AM-125 Phase 2 Trial in Acute Vertigo

2019-07-03 09:00:00 | Auris Medical Completes Enrollment of Phase 1b Proof-Of-Concept Trial of AM-201 in Antipsychotic-Induced Weight Gain

2019-06-13 09:50:01 | Savara Plunges on Failure of Late-Stage Study on Molgradex

2019-05-23 09:00:00 | Auris Medical Holding Ltd Provides Corporate Update

2019-05-20 08:45:00 | Auris Medical Holding Ltd Regains Compliance with Nasdaq Minimum Bid Price Rule

2019-05-15 16:15:00 | Auris Medical Announces Closing of Public Offering of Common Shares

2019-05-15 09:00:00 | Auris Medical Announces Closing of Two US Patent Acquisitions Related to the Use of Betahistine for the Treatment of Depression and ADHD

2019-05-13 08:30:00 | Auris Medical Holding Ltd.:

2019-05-07 09:00:00 | Auris Medical Reaches Midpoint for Enrollment in AM-201 Phase 1b Proof-of-Concept Study in Antipsychotic-Induced Weight Gain

2019-04-30 08:30:00 | Auris Medical Announces Reverse Stock Split

2019-04-25 09:00:00 | Auris Medical Provides Update on Tinnitus Drug Development Strategy

2019-04-18 12:11:18 | Buyer's Remorse? OTC Stock Zoom Technologies Zooms Higher Amid Potential Buyer Confusion

2019-04-15 09:00:00 | Auris Medical Receives Positive Nasdaq Listing Determination

2019-03-29 09:01:06 | Auris Medical Announces Randomization of First Dose Cohort in AM-201 Phase 1b Proof-of-Concept Study

2019-03-14 21:48:25 | Auris Medical Announces 20-F Filing

2019-03-14 14:30:00 | These Four Healthcare Stocks Could Test March Highs

2019-03-14 07:58:25 | Auris: 4Q Earnings Snapshot

2019-03-14 07:00:45 | Auris Medical Provides Business Update and Reports Fourth Quarter and Full Year 2018 Financial Results

2019-03-11 08:51:05 | Auris Medical Announces Publication of AM-111 Phase 3 Results in Peer-Reviewed Scientific Journal

2019-03-07 08:01:14 | Auris Medical to Report Fourth Quarter and Full Year 2018 Financial Results and Provide Business Update on Thursday, March 14, 2019

2019-02-13 10:42:25 | Case of Mistaken Identity Sends Auris Medical Shares Soaring 30%

2019-02-08 17:00:42 | Auris Medical Announces Receipt of Nasdaq Notice

2019-02-01 07:31:08 | Auris Medical Announces Full Repayment of Hercules Loan Facility

2019-01-29 07:31:00 | Auris Medical to Redomicile Holding Company from Switzerland to Bermuda

2019-01-23 09:45:00 | 4 Healthcare Stocks Making Moves On Wednesday 1/23/19

2019-01-23 08:31:00 | Auris Medical Announces Publication of New Data Highlighting the Role of Betahistine in Promoting the Restoration of Forgotten Memories in Mice and Healthy Volunteers

2019-01-15 08:31:06 | Auris Medical Provides Update on Intranasal Betahistine Programs

2018-12-31 16:08:01 | Penny Stocks to Buy Using Technical Analysis for January 2019

2018-12-06 09:15:00 | New Healthcare Trends Pushing Stocks Higher On Thursday

2018-12-06 07:31:08 | Auris Medical Announces Acquisition of Orphan Drug Designation and Secures Rights to In-License Additional Patents Related to Betahistine